Page 4 - ஜெநெரிக் பொறியியல் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from ஜெநெரிக் பொறியியல். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In ஜெநெரிக் பொறியியல் Today - Breaking & Trending Today

Reform has unleashed Chinese drugs innovation boom, though some pharma firms may not survive under intense price pressure, industry leaders say

Fast expansion of China’s ‘novel drugs’ market brings opportunity for developers of new medicines, forum hears, though price pressure could spell the end for those that fail to innovate. ....

Medi Cal , Health Care , மேதி கலோரி , ஆரோக்கியம் பராமரிப்பு ,

'Pharma must rethink, repurpose' - The Hindu BusinessLine


‘Pharma must rethink, repurpose’
Healing touch: YK Hamied, non-executive Chairman of Cipla   -  REUTERS×
Learn from past mistakes and acquire the right technology for the future, pharma doyen YK Hamied urges his compatriots
It’s 9.30 am when Dr YK Hamied calls from Spain, where he’s been for four months now, he says, due to pandemic-induced lockdowns and quarantines.
“It’s a sad situation,” he says, sounding uncharacteristically gloomy, as he quotes US expert Dr Anthony Fauci, who had cautioned ahead of the year-end festivities that the worst was yet to come.
The conversation veers to a recent development involving Dr Hamied, non-executive Chairman of home-grown drugmaker Cipla. A doyen of the pharma industry, Hamied was given a “lifetime achievement award” by the Organisation of Pharmaceutical Producers of India (OPPI), a platform largely of multinational drug companies. ....

Aurobindo Pharma after tieup with COVAXX for COVID-19 vaccine in India


COVAXX is currently conducting a Phase 1 clinical trial for the vaccine candidate.Aurobindo Pharma and US-based COVAXX have entered into an exclusive license agreement to develop, commercialize and manufacture UB-612, the first multitope peptide-based vaccine to fight COVID-19, for India and the United Nations Children s Fund (UNICEF) agency.
Under the signed agreement, Aurobindo Pharma has obtained the exclusive rights to develop, manufacture and sell COVAXX s UB-612 vaccine in India and to UNICEF, as well as non-exclusive rights in other select emerging and developing markets.
Aurobindo Pharma and COVAXX are partnering on clinical development, manufacturing and marketing of COVAXX s vaccine candidate, UB-612. The pharmaceutical company will manufacture the finished doses at its facilities in Hyderabad (Telangana). Aurobindo Pharma has the capacity of manufacturing 220 million doses in multi-dose presentation and is building additional facilities to have a total capacit ....

Aurobindo Pharma , United Nations Children Fund , United Nations Children , Capital Market , Health Sciences , Medical Research , Zika Virus , Zika Virus Vaccine , Sinovac Biotech , United Nations International Childrens Emergency Fund , N Govindarajan , அரவிந்தோ பார்மா , ஒன்றுபட்டது நாடுகள் குழந்தைகள் நிதி , ஒன்றுபட்டது நாடுகள் குழந்தைகள் , மூலதனம் சந்தை , தடுப்பு மருந்துகள் , ஆரோக்கியம் அறிவியல் , மருத்துவ ஆராய்ச்சி , ஜிக வைரஸ் , ஜிக வைரஸ் தடுப்பூசி , ஒன்றுபட்டது நாடுகள் சர்வதேச குழந்தைகள் அவசரம் நிதி , ச்சனியான கோவிந்தராஜன் ,